Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

CAMBREX CORPORATION (CBM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/13/2018 02/14/2018 02/15/2018 02/16/2018 02/20/2018 Date
54.95(c) 53.5(c) 52.9(c) 52.8(c) 51.95(c) Last
446 123 522 544 352 917 272 877 430 297 Volume
+3.29% -2.64% -1.12% -0.19% -1.61% Change
More quotes
Financials ($)
Sales 2018 536 M
EBIT 2018 123 M
Net income 2018 92,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 555 M
EBIT 2019 129 M
Net income 2019 98,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 19,17
P/E ratio 2019 17,91
Capi. / Sales2018 3,24x
Capi. / Sales2019 3,12x
Capitalization 1 734 M
More Financials
Company
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies to innovator and generic pharmaceutical companies.Its products include generic and branded APIs, controlled... 
Sector
Pharmaceuticals
Calendar
02/22 | 09:05pmPresentation
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
02/15Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conferen..
GL
02/13CAMBREX : up on innovator API demand, aims for double-digit growth
AQ
02/08CAMBREX : beats 4Q profit forecasts
AQ
02/08CAMBREX (NYSE : CBM) reported earnings of $1.27 per share beating Walls Streets ..
AQ
02/08CAMBREX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
02/08CAMBREX CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
02/08Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results
GL
02/08CAMBREX CORPORATION : to Host Earnings Call
AC
02/03CAMBREX : Expands API Development at Iowa Facility
AQ
02/02Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on Fe..
GL
More news
Sector news : Pharmaceuticals - NEC
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
02/16Intrust Bank NA Sells 1,643 Shares of Cambrex Co. $CBM  
02/15Want the latest analyst ratings on $PNG $CBM $PAA $NSSC $BEAT? Get Them Deliv.. 
02/15Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conferen.. 
02/15$CBM Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare Con.. 
02/15Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conferen.. 
More tweets
Qtime:32
News from SeekingAlpha
02/14Premarket analyst action - healthcare 
02/08Cambrex's (CBM) CEO Steven Klosk on Q4 2017 Results - Earnings Call Transcrip.. 
02/08Cambrex beats by $0.15, misses on revenue 
02/07Notable earnings before Thursday?s open 
2017RECRO PHARMACEUTICALS : Prescriptions For Pain Are A Prescription For Gain 
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 60,8 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Tom Vadaketh Chief Financial Officer & Vice President
Peter G. Tombros Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION11.46%1 734
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359